The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities. A report from McKinsey notes that the healthcare industry is now continuing to innovate and grow despite persistent inflation in consumer prices.
However, a volatile macro scenario and tight labor market could slow down its growth. Amid such a backdrop, let’s take a look at the five best and worst performing healthcare stocks in Q3 2022.
Five Best Performing Healthcare Stocks In Q3 2022
We have used the third-quarter return data from finviz.com to come up with the five best and worst performing healthcare stocks in Q3 2022. First let’s take a look at the five best-performing healthcare stocks in Q3 2022:
Q3 2022 hedge fund letters, conferences and more
-
Astria Therapeutics (198%)
Founded in 2008 and headquartered in Boston, Mass., this company discovers, develops and sells novel therapeutics. Astria Therapeutics Inc (NASDAQ:ATXS) shares are up by over 44% year to date and up almost 3% in the last month.
As of this writing, Astria Therapeutics shares are trading above $9.30 with a 52-week range of $2.36 to $12.86, giving the company a market capitalization of more than $145 million.
-
Heartbeam (210%)
Founded in 2015 and headquartered in Santa Clara, Calif., this company deals in cardiovascular diagnostic technology. Heartbeam Inc (NASDAQ:BEAT) shares are up by over 29% year to date and up almost 96% in the last month.
As of this writing, Heartbeam shares are trading above $3.90 with a 52-week range of $1.12 to $6.74, giving the company a market capitalization of more than $31 million.
-
Akero Therapeutics (235%)
Founded in 2017 and headquartered in South San Francisco, Calif., it is a cardio-metabolic nonalcoholic steatohepatitis company. Akero Therapeutics Inc (NASDAQ:AKRO) shares are up by over 90% year to date and up over 55% in the last month.
As of this writing, Akero Therapeutics shares are trading above $40 with a 52-week range of $7.52 to $42.20, giving the company a market capitalization of more than $1.80 billion.
-
Vigil Neuroscience (284%)
Founded in 2020 and headquartered in Cambridge, Mass., this company focuses on neurodegenerative diseases. Vigil Neuroscience Inc (NASDAQ:VIGL) shares are up by over 45% in the last month.
As of this writing, Vigil Neuroscience shares are trading above $13 with a 52-week range of $2.18 to $18.27, giving the company a market cap of more than $470 million.
-
Rhythm Pharmaceuticals (470%)
Founded in 2008 and headquartered in Boston, Mass., this company develops and sells peptide therapeutics to treat gastrointestinal diseases and genetic deficiencies. Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) shares are up by over 122% year to date and up over 3% in the last month.
As of this writing, Rhythm Pharmaceuticals shares are trading above $22 with a 52-week range of $3.04 to $30.98, giving the company a market capitalization of more than $1.24 billion.
Five worst performing healthcare stocks in Q3 2022
Here are the five worst-performing healthcare stocks in Q3 2022:
-
Otonomy (-86%)
Founded in 2008 and headquartered in San Diego, this company develops therapeutics for neurotology. Otonomy Inc (NASDAQ:OTIC) shares are down by almost 95% year to date and down over 59% in the last month.
As of this writing, Otonomy shares are trading above $0.112 with a 52-week range of $0.1022 to $2.5899, giving the company a market cap of more than $6 million.
-
FOXO Technologies (-87%)
Founded in 2019 and headquartered in Minneapolis, Minnesota, Foxo Technologies Inc (NYSEAMERICAN:FOXO) uses bioinformatics and microarray technologies to develop epigenetic biomarkers of health and aging. FOXO Technologies shares are down by almost 92% year to date and down almost 52% in the last month.
As of this writing, FOXO Technologies shares are trading above $0.83 with a 52-week range of $0.81 to $11.00, giving the company a market capitalization of more than $28 million.
-
Humanigen (-89%)
Founded in 2000 and headquartered in Essex County, N.J., this company develops cell and gene therapies for the treatment of cancers. Humanigen Inc (NASDAQ:HGEN) shares are down by over 95% year to date and down over 13% in the last month.
As of this writing, Humanigen shares are trading at above $0.150 with a 52-week range of $0.1451 to $8.3800, giving the company a market cap of more than $15 million.
-
Virios Therapeutics (-91%)
Founded in 2012 and headquartered in Alpharetta, Ga., this company develops antiviral therapies. Virios Therapeutics Inc (NASDAQ:VIRI) shares are down by over 94% year to date and down over 28% in the last month.
As of this writing, Virios Therapeutics shares are trading above $0.302 with a 52-week range of $0.2777 to $9.1109, giving the company a market capitalization of more than $5.70 million.
-
ContraFect (-95%)
Founded in 2008 and headquartered in Yonkers, N.Y., this company discovers and develops direct lytic agents (DLAs). ContraFect Corp (NASDAQ:CFRX) shares are down by over 93% year to date and down almost 11% in the last month.
As of this writing, ContraFect shares are trading above $0.157 with a 52-week range of $0.1501 to $4.5400, giving the company a market cap of more than $6 million.
